Category Archives: News

Inside-Out or Outside-In? How Organoid Polarity Shapes Nutrition and Drug Discovery Research

Epithelial polarity, the organized distinction between an apical surface (that faces lumen or the outside) and a basolateral surface (that interfaces with stroma and blood) is a fundamental feature of many tissues, especially the intestinal epithelium. In recent years, three-dimensional (3D) organoid models have become central to nutrition, pharmacology, infection biology, and personalized medicine because […]

See you at SfN – Neuroscience 2025

Discover the Future of 3D Cell Culture at SfN – Neuroscience 2025 We’re excited to announce our first-ever participation at Neuroscience 2025! Join us on November 15–19, 2025, at the San Diego Convention Center to explore how VitroGel®, our xeno-free, synthetic hydrogel system, is driving the shift toward animal-free, reproducible, and scalable 3D cell culture […]

TheWell Bioscience Launches VitroGel® NEURON, a First-Of-Its-Kind Synthetic Hydrogel for Superior 3D, 2D Neuronal Cell Culture and Beyond

Monmouth Junction, NJ –  TheWell Bioscience Inc., a leader in advanced 3D cell culture platforms for precision medicine, cell therapy, and biomanufacturing, announces the launch of VitroGel® NEURON, a groundbreaking synthetic and xeno-free hydrogel specifically engineered to overcome the limitations of animal-derived matrices by supporting both 3D and 2D neuronal culture and serving as an […]

Xeno-Free 2D and 3D Neuron Culture Made Easy with VitroGel® NEURON

VitroGel® NEURON is a xeno-free hydrogel designed to closely mimic the native extracellular matrix, supporting the growth, differentiation, and maturation of neuronal cells. With its user-friendly, ready-to-use formulation, scientists can seamlessly transition between 2D and 3D cultures without the need for animal-derived components — significantly improving experimental consistency and translational relevance.

Time to Cut the Cord: Why Animal-Based ECMs Have No Place in the Future of 3D Cell Models

In April 2025, the U.S. Food and Drug Administration (FDA) announced a groundbreaking initiative to phase out the animal testing requirement for monoclonal antibodies and other drugs. This marked a significant milestone in the advancement of preclinical research. Experts from regulatory agencies, academia, and industry worldwide convened to promote the adoption of New Approach Methodologies […]